Overall survival of patients with metastatic breast cancer in Sweden: a nationwide studyVisa övriga samt affilieringar
2022 (Engelska)Ingår i: British Journal of Cancer, ISSN 0007-0920, E-ISSN 1532-1827, Vol. 127, nr 4, s. 720-725Artikel i tidskrift (Refereegranskat) Published
Abstract [en]
Background: Breast cancer is the most common cancer among women in Sweden. Whereas survival for the overall breast cancer population is well-documented, survival of patients with metastatic breast cancer (MBC) is harder to quantify due to the lack of reliable data on disease recurrence in national cancer registers. Methods: This study used machine learning to classify the total MBC population in Sweden diagnosed between 2009 and 2016 using national registers, with the aim to estimate overall survival (OS). Results: The total population consisted of 13,832 patients—2528 (18.3%) had de novo MBC whereas 11,304 (81.7%) were classed as having a recurrent MBC. Median OS for patients with MBC was found to be 29.8 months 95% confidence interval (CI) [28.9, 30.6]. Hormone-receptor (HR)-positive MBC had a median OS of 37.0 months 95% CI [35.9, 38.3] compared to 9.9 months 95% CI [9.1, 11.0] for patients with HR-negative MBC. Conclusion: This study covered the entire MBC population in Sweden during the study time and may serve as a baseline for assessing the effect of new treatment strategies in MBC introduced after the study period.
Ort, förlag, år, upplaga, sidor
Springer Nature, 2022. Vol. 127, nr 4, s. 720-725
Nationell ämneskategori
Cancer och onkologi
Identifikatorer
URN: urn:nbn:se:umu:diva-203223DOI: 10.1038/s41416-022-01845-zISI: 000799700200002PubMedID: 35597870Scopus ID: 2-s2.0-85130306404OAI: oai:DiVA.org:umu-203223DiVA, id: diva2:1728131
2023-01-172023-01-172023-05-24Bibliografiskt granskad